Ask AI

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Share

Program Content

Activities

INCA033989 in ET
Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner